 |
Business Strategy
Our highly experienced staff is constantly seeking new technologies within technology transfer offices at universities and other research centers around the world to expand our portfolio of diagnostic technologies.
What We Do
- Aggressive in-licensing of diagnostic biomarkers that have the potential to change patient management
- Select prototype technologies, eliminating exploratory research phase, increasing pipeline hit rate
- Acquire a steady stream of new products for development
- Outsource special technical, patent, regulatory, and manufacturing requirements
- Add value to products through development activities
- Out-license products or patent rights or commercialize products directly
Why The Strategy Works
Hundreds of potential diagnostic product candidates lie dormant in university research labs
- Fundamental research is complete
- Patents are usually written and filed
- Funding to further develop the technology is often required
- Publications are primary work product of researchers, not products
Ability to pick and choose technologies with the greatest potential
- Strong patent position
- Unique characteristics of marker(s)
- Scientific credibility of lead researcher and institution
Virtual company model is flexible
- Employ individuals with core competencies and relevant experience
- Maintain a stable of advisors, consultants and contractors to evaluate and develop technologies
- Minimal capital investment
- Not restricted to one platform
Risk is reduced
- Option to license allows for due diligence process and reduces up-front costs
- Discard weak technologies at an early stage
- Compile a portfolio of varied risk and time to market technologies
|
|
|
|
|
